letrozole,palbociclib
pfizer,novartis
['paloma-2', 'palbociclib']
 paloma-2 trial: #palbociclib is currently one step behind the others cdk4/6 inhib. in 1l therapy. the key secondary endpoint of this trial, os, was numerically longer but not statistically significant: 53.9 vs 51.2 mo (hr 0.956 p=0.3378). #asco22 #bcareporter 